InspireMD, Inc. (NASDAQ:NSPR) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
Chuck Padala - Investor Relations
Marvin Slosman - Chief Executive Officer
Craig Shore - Chief Financial Officer
Conference Call Participants
Benjamin Haynor - Alliance Global Partners
Operator
Good morning, and welcome to the InspireMD Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this conference is being recorded.
I would now like to turn the conference over to Chuck Padala with LifeSci Advisors. Thank you. You may begin.
Chuck Padala
Thank you, operator, and good morning, everyone. Thank you for joining us for the InspireMD Second Quarter 2022 Financial Results and Corporate Update Conference Call.
Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer; and Craig Shore, Chief Financial Officer.
During this call, management will be making forward-looking statements, not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. They involve risks and uncertainties that may cause actual results to differ materially from those expressed in the forward-looking statements.
More information about these risks, please refer to the risk factors described in InspireMD's most recently filed periodic reports on Form 10-K and Form 10-Q filed with the U.S. Securities and Exchange Commission, and InspireMD's press release that accompanies this call, particularly the cautionary statements made in it.
The call contains time-sensitive information that is accurate only as of today, August 9, 2022. Except as required by law, InspireMD disclaims any obligations to publicly update or revise any information to reflect events or circumstances that occur after this call.
It is now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.
Marvin Slosman
Thank you, Chuck, and thanks to everyone for joining our call this morning. During the second quarter, we continued to successfully execute on our mission to establish a new paradigm in standard of care for carotid artery disease treatment and stroke prevention. The clear highlight was revenue totaling $1.5 million, which represents a growth of nearly 48% as compared to the second quarter of last year. This increase was driven by sales of our CGuard Embolic Prevention Stent System.
When you ignore the strengthening of the U.S. dollar versus the euro of approximately 12%, our volume of units sold actually increased by 60%, which represented 2,602 units sold this quarter versus 1,623 in Q2 of 2021 and 1,910 units sold last quarter.